Quince Therapeutics Inc
NASDAQ:QNCX 4:00:00 PM EDT
Layoffs, Earnings Announcements
Quince Therapeutics Approved Cost Reduction Program
Published: 01/30/2023 21:44 GMT
Quince Therapeutics Inc (QNCX) - Quince Therapeutics - on January 24, Board of Company Approved Cost Reduction Program to Align Operations With Changes in Corporate Strategy.
Quince Therapeutics - Under Plan, Company is Reducing Headcount by Approximately 47% Through a Reduction in Its Workforce.
Quince Therapeutics - Reduction in Force Will Begin in February 2023 and Will Be Completed by April 2023.
Quince Therapeutics - As a Result, Expects to Realize Estimated Annualized Operating Expense Savings of About $9.5 Million in Year Ending Dec 31, 2023.
Quince Therapeutics - Reduction in Force Will Begin in February 2023 and Will Be Completed by April 2023.
Quince Therapeutics - Expects to Realize Estimated Annualized Operating Expense Savings of Approximately $9.5 Million in Year Ending December 31, 2023.
Quince Therapeutics - in Connection With Plan, Company Estimates That It Will Incur Expenses of Approximately $0.6 Million to $0.8 Million.
Further Company Coverage: Qncxo ((reuters.
Briefs@thomsonreuters.
Com;)).
Quince Therapeutics - Under Plan, Company is Reducing Headcount by Approximately 47% Through a Reduction in Its Workforce.
Quince Therapeutics - Reduction in Force Will Begin in February 2023 and Will Be Completed by April 2023.
Quince Therapeutics - As a Result, Expects to Realize Estimated Annualized Operating Expense Savings of About $9.5 Million in Year Ending Dec 31, 2023.
Quince Therapeutics - Reduction in Force Will Begin in February 2023 and Will Be Completed by April 2023.
Quince Therapeutics - Expects to Realize Estimated Annualized Operating Expense Savings of Approximately $9.5 Million in Year Ending December 31, 2023.
Quince Therapeutics - in Connection With Plan, Company Estimates That It Will Incur Expenses of Approximately $0.6 Million to $0.8 Million.
Further Company Coverage: Qncxo ((reuters.
Briefs@thomsonreuters.
Com;)).